Dr. C.F. Shah and his Innovations Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Product Cost: Production cost for the device is approximately 1,500 INR (Exhibit 2).
Market Price: Proposed retail price is 5,000 INR (Case text).
Financial Goal: Dr. Shah seeks to maintain a 30% margin while ensuring affordability for rural clinics (Paragraph 12).

Operational Facts

Innovation: A low-cost, portable diagnostic device for rural health centers (Paragraph 1).
Production: Currently relies on local artisans; scalability is limited (Paragraph 8).
Geography: Targeted at rural India, specifically districts with limited access to diagnostic infrastructure (Paragraph 3).

Stakeholder Positions

Dr. C.F. Shah: Founder, prioritizes social impact and clinical accessibility over rapid profit (Paragraph 5).
Investors: Seeking a clear path to profitability and evidence of scalability before further funding (Paragraph 14).
Rural Health Centers: Interested in the technology but lack the technical staff to operate complex equipment (Paragraph 9).

Information Gaps

Supply Chain: No data on long-term component availability or vendor contracts.
Regulatory: Missing documentation on medical device certification status in India.
Distribution: No clear plan for maintenance or after-sales support in remote regions.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How can Dr. Shah scale production and distribution while maintaining clinical integrity and financial viability in resource-constrained rural markets?

Structural Analysis

Value Chain: The current reliance on artisanal production is a bottleneck. Moving to modular assembly is required for volume.
Jobs-to-be-Done: The rural health center needs a diagnostic result, not just a device. The innovation must shift from selling hardware to providing a service.

Strategic Options

Option A: Direct Sales to Rural Clinics. High friction due to procurement processes. Rejected: Clinics lack the capital and staff training capacity.
Option B: B2B Partnership with NGO Networks. Utilize existing rural health infrastructure. Rationale: Reduces distribution costs and leverages trusted local intermediaries.
Option C: Licensing Model. Sell the design to larger manufacturers. Rationale: Rapid scale. Trade-off: Loss of control over pricing and social mission.

Preliminary Recommendation

Pursue Option B. Partner with established NGOs to bundle the device with training services. This ensures the device is used correctly and creates a recurring revenue stream through maintenance contracts.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Months 1-3: Finalize design for modular assembly and secure regulatory certification.
Months 4-6: Pilot program with three selected NGO partners in diverse geographic zones.
Months 7-9: Establish a centralized training program for health workers.

Key Constraints

Technical Literacy: The device must be usable by non-specialist staff.
Infrastructure: Reliability of power supply and network connectivity for data transmission.

Risk-Adjusted Implementation

Contingency: If NGO adoption is slower than expected, pivot to a hub-and-spoke model where the device is centrally managed by a regional clinic serving multiple sub-centers.

4. Executive Review and BLUF (Executive Critic)

BLUF

Dr. Shah must stop viewing the device as a product and start viewing it as a service. The current artisanal production model will fail under any meaningful volume. He should adopt a B2B model, partnering with NGOs to handle distribution and training. This preserves his mission while offloading the operational burden of direct sales. If the device cannot be operated by a trained nurse with minimal clinical background, it is not ready for the rural market. Development effort must shift from the hardware to the user interface and remote diagnostic support.

Dangerous Assumption

The assumption that rural clinics have the capability to maintain and calibrate the device independently. They do not. Without a service-level agreement or centralized maintenance, the devices will be discarded within 12 months.

Unaddressed Risks

Regulatory Risk: High likelihood of certification delays. If this occurs, the entire 90-day plan is stalled.
Capital Risk: The current pricing of 5,000 INR may be insufficient if maintenance costs are higher than projected.

Unconsidered Alternative

Direct-to-consumer mobile diagnostic service. Instead of selling devices, Dr. Shah could deploy mobile units equipped with the devices, moving the cost from capital expenditure to an operational fee-per-test model.